>
Switch to:

Intec Parent EV-to-EBITDA

: -0.65 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Intec Parent's enterprise value is $8.37 Mil. Intec Parent's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $-12.85 Mil. Therefore, Intec Parent's EV-to-EBITDA for today is -0.65.

The historical rank and industry rank for Intec Parent's EV-to-EBITDA or its related term are showing as below:

NAS:NTEC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.61   Med: 0   Max: 0
Current: -0.65

-1.61
0
NAS:NTEC's EV-to-EBITDA is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 17.53 vs. NAS:NTEC: -0.65 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-10-24), Intec Parent's stock price is $9.63. Intec Parent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $. Therefore, Intec Parent's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Intec Parent EV-to-EBITDA Historical Data

The historical data trend for Intec Parent's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only -3.58 -2.76 -4.94 -0.29 -0.09

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.38 -0.34 -0.09 -0.80

Competitive Comparison

For the Biotechnology subindustry, Intec Parent's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intec Parent EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Intec Parent's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Intec Parent's EV-to-EBITDA falls into.



Intec Parent EV-to-EBITDA Calculation

Intec Parent's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.369/-12.845
=-0.65

Intec Parent's current Enterprise Value is $8.37 Mil.
Intec Parent's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intec Parent  (NAS:NTEC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Intec Parent's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.63/-14.945
=At Loss

Intec Parent's share price for today is $9.63.
Intec Parent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Intec Parent EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Intec Parent's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent Business Description

Intec Parent logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Linscott Walt Addison officer: Chief Business Officer 1860 MONTREAL ROAD TUCKER GA 30084
Sassi Nir officer: Chief Financial Officer 3 ELUL STREET, APT. 6 MODIIN L3 7176397
Navon Nadav officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Maddaluna Anthony J director PFIZER INC. ATTN CORPORATE SECRETARY 235 RAST 42ND STREET NEW YORK NY 10017
Hayes William B director 231 MAPLE AVENUE BURLINGTON NC 27215
Pomerantz Roger director 711 HARVEST HILL ROAD CHALFONT PA 18914
Karah Hila director 9 HALAMISH STREET CAESAREA INDUSTRIAL PARK CAESAREA L3 38900
Kozarich John W director 10275 SCIENCE CENTER DR SAN DIEGO CA 92121
Meckler Jeffrey A director, officer: Chief Executive Officer 740 BROADWAY 9TH FLOOR NEW YORK NY 10003
Gendreau R Michael officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Oren Dan 10 percent owner 1 DEXCEL STREET OR AKIVA L3 30600000
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET OR AKIVA L3 3060000
Bianco Gil director 7 HAORANIM STREET BAZRA L3 60944
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)